Surgery, Gastroenterology and Oncology
Official journal of the International Association of Surgeons, Gastroenterologists and Oncologists
|
|
Evaluation of Axillary Clearance and Whole Breast Radiotherapy for Occult Primary Breast Carcinoma Presented with Axillary Metastases Not Detected by MRI
Background: This study aimed to assess the overall survival and disease-free survival after axillary lymph node dissection (ALND) and whole breast radiotherapy (WBRT).
Methods: This was a prospective cohort study. Twenty female patients with enlarged ALN metastasis of breast origin with occult primary tumor not detected by MRI were recruited for ALND and WBRT with or without neoadjuvant chemotherapy.
Results: Twenty of 1823 patients (1%) were diagnosed with axillary metastasis of breast origin with occult primary breast carcinoma (OBC) not detected by MRI. Sixteen patients (80%) have N1 disease, sixteen (80%) were estrogen receptorâ?"positive, four (20%) were HERII-positive and two (10%) were triple negative. Eighteen patients (90%) underwent ALND with WBRT and two (10%) underwent sentinel lymph node biopsy with WBRT. Five patients (25%) received neoadjuvant chemotherapy and two of them (40%) gave complete pathological response. No local recurrence in the follow-up period was detected. All patients will be followed after 3 years and 5 years as regard disease free survival & overall survival.
Conclusions: Due to limited experience in OBC, the optimal treatment is not yet established. There was no difference between modified radical mastectomy and ALND with WBRT as regard overall survival and disease-free survival.
Full Text Sources:
Abstract:
Views: 1793
Methods: This was a prospective cohort study. Twenty female patients with enlarged ALN metastasis of breast origin with occult primary tumor not detected by MRI were recruited for ALND and WBRT with or without neoadjuvant chemotherapy.
Results: Twenty of 1823 patients (1%) were diagnosed with axillary metastasis of breast origin with occult primary breast carcinoma (OBC) not detected by MRI. Sixteen patients (80%) have N1 disease, sixteen (80%) were estrogen receptorâ?"positive, four (20%) were HERII-positive and two (10%) were triple negative. Eighteen patients (90%) underwent ALND with WBRT and two (10%) underwent sentinel lymph node biopsy with WBRT. Five patients (25%) received neoadjuvant chemotherapy and two of them (40%) gave complete pathological response. No local recurrence in the follow-up period was detected. All patients will be followed after 3 years and 5 years as regard disease free survival & overall survival.
Conclusions: Due to limited experience in OBC, the optimal treatment is not yet established. There was no difference between modified radical mastectomy and ALND with WBRT as regard overall survival and disease-free survival.
Full Text Sources:
Abstract:
Views: 1793
Watch Video Articles
For Authors
Journal Subscriptions
Current Issue
Dec 2025
Supplements
Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
- SCOPUS
- EBSCO
- DOI/Crossref
- Google Scholar
- SCImago
- Harvard Library
- Open Academic Journals Index (OAJI)
Open Access Statement
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Journal Metrics
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
IASGO Society News
Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.